Literature DB >> 9394837

Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions.

N Kerlero de Rosbo1, M Hoffman, I Mendel, I Yust, J Kaye, R Bakimer, S Flechter, O Abramsky, R Milo, A Karni, A Ben-Nun.   

Abstract

Our previous analysis of the T cell reactivity to myelin antigens in a group of 24 patients with multiple sclerosis (MS) and 16 control individuals revealed that the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) predominates in MS over that to myelin basic protein (MBP), proteolipid protein or myelin-associated glycoprotein, suggesting a prevalent role for the autoimmune response to MOG in the pathogenesis of MS. Using a recombinant human MOG (rhMOG) preparation corresponding to the extracellular immunoglobulin-like domain of the MOG molecule, we have now analyzed another group of 52 MS patients and 49 control individuals for reactivity of their peripheral blood lymphocytes (PBL) to rhMOG and to MBP concomitantly. Of the 52 MS patients tested 24 responded to MOG and 10 out of 49 responded to MBP, whereas only 5 MOG-reactive and 4 MBP-reactive control individuals were detected out of the 49 tested. These results are therefore highly confirmatory of the predominant reactivity to MOG in MS. The analysis of the primary proliferative response to 11 synthetic overlapping peptides (phMOG) spanning the extracellular domain of human MOG by PBL from 9 MS patients and 15 control individuals (9 healthy controls and 6 patients with neurological diseases other than MS) further supports a prevalent role for the autoimmune response to MOG in MS, as only 1 of the 15 controls tested showed reactivity to any of the phMOG, whilst 5 out of the 9 patients studied reacted to at least 1 of the phMOG. PBL from 10 MS patients, and from 4 controls, were selected in vitro with each of the phMOG. Of the 10 patients studied 7 reacted to at least 1 phMOG upon secondary stimulation and the reactivity was mostly directed to epitopes localized within three main regions (amino acids 1-22, 34-56 and 64-96), as was observed for the primary response of PBL. The predominant response to MOG of PBL from MS patients as demonstrated in two separate studies using native MOG and rhMOG as antigens, and the high incidence of reactivity of these PBL compared to the lack of response to phMOG by control PBL, emphasize the relevance of MOG in MS pathogenesis and support a primary role for the autoimmune T cell response to MOG in disease development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9394837     DOI: 10.1002/eji.1830271144

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  30 in total

1.  Immune modulation by a tolerogenic myelin oligodendrocyte glycoprotein (MOG)10-60 containing fusion protein in the marmoset experimental autoimmune encephalomyelitis model.

Authors:  Y S Kap; N van Driel; R Arends; G Rouwendal; M Verolin; E Blezer; N Lycke; B A 't Hart
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

2.  Skewed autoantibody reactivity to the extracellular domain of myelin oligodendrocyte glycoprotein in multiple sclerosis.

Authors:  Maria V Tejada-Simon; Jian Hong; Victor M Rivera; Jingwu Z Zhang
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 3.  Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.

Authors:  H C von Büdingen; N Tanuma; P Villoslada; J C Ouallet; S L Hauser; C P Genain
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

4.  Direct activation of innate and antigen-presenting functions of microglia following infection with Theiler's virus.

Authors:  J K Olson; A M Girvin; S D Miller
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.

Authors:  Christopher T Harp; Sara Ireland; Laurie S Davis; Gina Remington; Bonnie Cassidy; Petra D Cravens; Olaf Stuve; Amy E Lovett-Racke; Todd N Eagar; Benjamin M Greenberg; Michael K Racke; Lindsay G Cowell; Nitin J Karandikar; Elliot M Frohman; Nancy L Monson
Journal:  Eur J Immunol       Date:  2010-10       Impact factor: 5.532

6.  Evaluation of locomotor function and microscopic structure of the spinal cord in a mouse model of experimental autoimmune encephalomyelitis following treatment with syngeneic mesenchymal stem cells.

Authors:  Nilesh Kumar Mitra; Umesh Bindal; Wong Eng Hwa; Caroline L L Chua; Chek Ying Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

7.  Increased frequencies of myelin oligodendrocyte glycoprotein/MHC class II-binding CD4 cells in patients with multiple sclerosis.

Authors:  Khadir Raddassi; Sally C Kent; Junbao Yang; Kasia Bourcier; Elizabeth M Bradshaw; Vicki Seyfert-Margolis; Gerald T Nepom; William W Kwok; David A Hafler
Journal:  J Immunol       Date:  2011-06-08       Impact factor: 5.422

Review 8.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

9.  Multiple sclerosis patients show sexual dimorphism in cytokine responses to myelin antigens.

Authors:  Ioana R Moldovan; Anne C Cotleur; Natacha Zamor; Robert S Butler; Clara M Pelfrey
Journal:  J Neuroimmunol       Date:  2007-11-26       Impact factor: 3.478

10.  The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis.

Authors:  Craig S Clements; Hugh H Reid; Travis Beddoe; Fleur E Tynan; Matthew A Perugini; Terrance G Johns; Claude C A Bernard; Jamie Rossjohn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.